Clinical Outcomes at 8-16 Weeks After Upadacitinib Initiation for Acute Severe Ulcerative Colitis: A Case Series in the United States

Rahul S Dalal; Rachel W Winter; Sanchit Gupta; Gila F Sasson; Matthew J Hamilton; Jessica R Allegretti

doi:10.1093/ibd/izae038

Clinical Outcomes at 8-16 Weeks After Upadacitinib Initiation for Acute Severe Ulcerative Colitis: A Case Series in the United States

Inflamm Bowel Dis. 2024 Jun 3;30(6):1042-1043. doi: 10.1093/ibd/izae038.

Authors

Rahul S Dalal¹, Rachel W Winter¹, Sanchit Gupta¹, Gila F Sasson¹, Matthew J Hamilton¹, Jessica R Allegretti¹

Affiliation

¹ Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

PMID: 38408096
DOI: 10.1093/ibd/izae038

No abstract available

Plain language summary

In 9 patients hospitalized for acute severe ulcerative colitis, 8 were successfully discharged without the need for colectomy. Six of 7 patients with sufficient follow-up achieved steroid-free clinical remission at 8 to 16 weeks, and 1 of 2 patients achieved endoscopic response.

Publication types

Letter

MeSH terms

Acute Disease
Adult
Colitis, Ulcerative* / drug therapy
Female
Heterocyclic Compounds, 3-Ring* / administration & dosage
Heterocyclic Compounds, 3-Ring* / therapeutic use
Humans
Male
Middle Aged
Severity of Illness Index
Treatment Outcome
United States

Substances

upadacitinib
Heterocyclic Compounds, 3-Ring